Célio Castro-Junior

Dr. Célio Castro-Junior


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2013 in Neuropharmacology
Verified
Journal Article
Closed access
CCCélio Castro-Junior
Célio Castro-Junior
JMJulie Milano
Julie Milano
ASAlessandra H. Souza
Alessandra H. Souza
JSJuliana F. Silva
Juliana F. Silva
FRFlávia K. Rigo
Flávia K. Rigo
MGMarcus V. Gomez
Marcus V. Gomez

16 June 2017 in Life Sciences
Verified
Journal Article
Closed access
MPManuella R. Palhares
Manuella R. Palhares
JSJuliana F. Silva
Juliana F. Silva
MRMarcio Junior S. Rezende
Marcio Junior S. Rezende
DSDuana C. Santos
Duana C. Santos
CSCláudio A. Silva-Junior
Cláudio A. Silva-Junior
CCCélio Castro-Junior
Célio Castro-Junior

1 December 2015 in Toxicon
Verified
Journal Article
Closed access
JSJuliana Figueira da Silva
Juliana Figueira da Silva
CCCélio Castro-Junior
Célio Castro-Junior
SOSara Marchesan Oliveira
Sara Marchesan Oliveira
GDGerusa Duarte Dalmolin
Gerusa Duarte Dalmolin
CSCássia Regina Silva
Cássia Regina Silva
MGMarcus Vinicius Gomez
Marcus Vinicius Gomez

1 January 2020 in Neuropharmacology
Verified
Journal Article
Closed access
EPElizete Maria Rita Pereira
Elizete Maria Rita Pereira
JSJéssica Mabelle Souza
Jéssica Mabelle Souza
NCNatália Virtude Carobin
Natália Virtude Carobin
JSJuliana Figueira Silva
Juliana Figueira Silva
DSDuana Carvalho Santos
Duana Carvalho Santos
MGMarcus Vinicius Gomez
Marcus Vinicius Gomez

11 March 2016 in Toxins
Verified
Journal Article
Open access
PDF file
NBNancy Binda
Nancy Binda
CCCharles Porto Petruceli Carayon
Charles Porto Petruceli Carayon
RARafael Mourão Agostini
Rafael Mourão Agostini
APAna Cristina Do Nascimento Pinheiro
Ana Cristina Do Nascimento Pinheiro
MCMarta Nascimento Cordeiro
Marta Nascimento Cordeiro
MGMarcus Vinicius Gomez
Marcus Vinicius Gomez
The in vivo neuroprotective effect of PhTx3-4, a spider toxin N-P/Q calcium channel blocker, was studied in a rat model of NMDA-induced injury of the retina. NMDA (N-Methyl-d-Aspartate)-induced retinal injury in rats reduced the b-wave amplitude by 62% ± 3.6%, indicating the severity of the insult. PhTx3-4 treatment increased the amplitude of the b-wave, which was almost equivalent to the control retinas that were not submitted to injury. The PhTx3-4 functional protection of the retinas recorded on the ERG also was observed in the neuroprotection of retinal cells. NMDA-induced injury reduced live cells in the retina layers and the highest reduction, 84%, was in the ganglion cell layer. Notably, PhTx3-4 treatment caused a remarkable reduction of dead cells in the retina layers, and the highest neuroprotective effect was in the ganglion cells layer. NMDA-induced cytotoxicity of the retina increased the release of glutamate, reactive oxygen species (ROS) production and oxidative stress. PhTx3-4 treatment reduced glutamate release, ROS production and oxidative stress measured by malondialdehyde. Thus, we presented for the first time evidence of in vivo neuroprotection from NMDA-induced retinal injury by PhTx3-4 (-ctenitoxin-Pn3a), a spider toxin that blocks N-P/Q calcium channels.

1 January 2021 in Journal of Venomous Animals and Toxins including Tropical Diseases
Verified
Journal Article
Open access
JSJuliana Figueira da Silva
Juliana Figueira da Silva
NBNancy Scardua Binda
Nancy Scardua Binda
EPElizete Maria Rita Pereira
Elizete Maria Rita Pereira
MLMário Sérgio Lima de DE LAVOR
Mário Sérgio Lima de DE LAVOR
Luciene Bruno VieiraLuciene Bruno Vieira
Luciene Bruno Vieira
MGMarcus Vinicius Gomez
Marcus Vinicius Gomez
Phα1β is a neurotoxin purified from spider venom that acts as a high-voltage-activated (HVA) calcium channel blocker. This spider peptide has shown a high selectivity for N-type HVA calcium channels (NVACC) and an analgesic effect in several animal models of pain. Its activity was associated with a reduction in calcium transients, glutamate release, and reactive oxygen species production from the spinal cord tissue and dorsal ganglia root (DRG) in rats and mice. It has been reported that intrathecal (i.t.) administration of Phα1β to treat chronic pain reverted opioid tolerance with a safer profile than ω-conotoxin MVIIA, a highly selective NVACC blocker. Following a recent development of recombinant Phα1β (CTK 01512-2), a new molecular target, TRPA1, the structural arrangement of disulphide bridges, and an effect on glial plasticity have been identified. CTK 01512-2 reproduced the antinociceptive effects of the native toxin not only after the intrathecal but also after the intravenous administration. Herein, we review the Phα1β antinociceptive activity in the most relevant pain models and its mechanisms of action, highlighting the impact of CTK 01512-2 synthesis and its potential for multimodal analgesia.